INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 128 filers reported holding INOVIO PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $322,574 | -59.8% | 829,238 | -53.9% | 0.00% | -50.0% |
| Q2 2023 | $802,914 | +21.8% | 1,798,240 | +325.6% | 0.00% | 0.0% |
| Q4 2022 | $659,139 | -79.9% | 422,525 | -77.7% | 0.00% | -81.8% |
| Q3 2022 | $3,275,000 | -58.7% | 1,898,394 | -58.5% | 0.01% | -57.7% |
| Q2 2022 | $7,923,000 | -5.6% | 4,579,636 | +95.8% | 0.03% | +4.0% |
| Q1 2022 | $8,395,000 | +1562.4% | 2,338,415 | +1428.3% | 0.02% | +1150.0% |
| Q4 2019 | $505,000 | +1385.3% | 153,006 | +820.3% | 0.00% | – |
| Q3 2019 | $34,000 | -90.5% | 16,625 | -86.3% | 0.00% | -100.0% |
| Q2 2019 | $357,000 | -28.7% | 121,381 | -9.7% | 0.00% | -50.0% |
| Q1 2019 | $501,000 | -28.4% | 134,368 | -23.2% | 0.00% | -33.3% |
| Q4 2018 | $700,000 | -16.4% | 175,059 | +16.3% | 0.00% | +50.0% |
| Q3 2018 | $837,000 | +754.1% | 150,482 | +498.9% | 0.00% | – |
| Q2 2018 | $98,000 | – | 25,127 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |